Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12862681 | 0.80 | AKR1B1 (0.44) | PDK2PDK4AKR1B1PGRCREBBP | |
| SCHEMBL24112426 | 0.79 | PDK2 (0.53) | PDK2PDK4AKR1B1PGRDAO | |
| SCHEMBL17810256 | 0.78 | AKR1B1 (0.45) | PDK2PDK4AKR1B1CREBBPPOLB | |
| SCHEMBL3865185 | 0.78 | PDK2 (0.52) | PDK2PDK4PGRPOLBPDK1 | |
| SCHEMBL31381642 | 0.78 | PDK2 (0.52) | PDK2PDK4PGRPOLBPDK1 | |
| SCHEMBL3150359 | 0.78 | PDK2 (0.52) | PDK2PDK4PGRPDK1PDK3 | |
| SCHEMBL3149249 | 0.78 | PDK2 (0.52) | PDK2PDK4PGRPDK1PDK3 | |
| SCHEMBL30484130 | 0.78 | PDK2 (0.52) | PDK2PDK4PGRPDK1PDK3 | |
| SCHEMBL24450280 | 0.77 | AKR1B1 (0.42) | PDK2PDK4AKR1B1PGRCREBBP | |
| SCHEMBL24029212 | 0.77 | AKR1B1 (0.42) | PDK2PDK4AKR1B1PGRCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015251-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4219449-A2 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF PREPARATION THEREOF | Kura Oncology, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4006030-A2 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022109179-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3429585-B1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3303317-B1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6166040-A | Indole compounds | ELI LILLY AND COMPANY LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-4933336-A | Thiadiazinone, oxadiazinone and triazinone derivatives, and their use for treating acute or chronic heart disease | LABORATOIRES SOBIO S.A. (FR) | 1990-06-12 | — | — | US | disclosed |
| EP-0303418-A2 | Substituted indolones, useful in the treatment of heart or asthmatic diseases | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | MLLT1, MEN1, BMI1 | PDK2 2965/4885PDK4 3093/4885AKR1B1 4214/4885 |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | PDK2 2466/4885PDK4 2414/4885AKR1B1 4239/4885 |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | PDK2 2556/4885PDK4 2817/4885AKR1B1 922/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | PDK2 1988/4885PDK4 2358/4885AKR1B1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.